Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Omkar S. Marathe

Hematology Oncology | Hematology | Oncology
The Oncology Institute Ca, A Professional Corporation
3851 Katella Ave, Suite 355, 
Los Alamitos, CA 
Clinical Trials:Currently Recruiting for 3 Trials
Offers Telehealth
Experienced in WT1-Related Wilms Tumor Syndromes
The Oncology Institute Ca, A Professional Corporation
3851 Katella Ave, Suite 355, 
Los Alamitos, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Omkar Marathe is a Hematologist Oncology specialist and a Hematologist in Los Alamitos, California. Dr. Marathe is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Colorectal Cancer, Thrombocytopenia, Colorectal Cancer, and Childhood Iron Deficiency Anemia.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Memorialcare Long Beach Medical Center
St Mary Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

THE ONCOLOGY INSTITUTE CA, A PROFESSIONAL CORPORATION
3851 Katella Ave, Suite 355, Los Alamitos, CA 90720

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
Enrollment Status: Recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 2
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: February 27, 2025
Intervention Type: Combination product, Drug
Study Phase: Phase 1/Phase 2
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drug: ZW25 (Zanidatamab)
Study Phase: Phase 2
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects With Beta Thalassemia
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects With Beta Thalassemia
Enrollment Status: Terminated
Publish Date: May 15, 2025
Intervention Type: Drug
Study Drug: IMR-687
Study Phase: Phase 2
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Enrollment Status: Unknown
Publish Date: March 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Enrollment Status: Terminated
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Trilaciclib, Docetaxel
Study Phase: Phase 2
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

4 Total Publications

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.
Journal: BJC reports
Published: August 15, 2024
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert A. Figlin
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert A. Figlin
Hematology Oncology | Hematology | Oncology

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (26.2 miles away)
310-423-5000
Languages Spoken:
English
See accepted insurances

Robert Figlin is a Hematologist Oncology specialist and a Hematologist in West Hollywood, California. Dr. Figlin is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nataliya Mar
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nataliya Mar
Hematology Oncology | Hematology | Oncology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (10.1 miles away)
714-456-7004
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nataliya Mar is a Hematologist Oncology specialist and a Hematologist in Orange, California. Dr. Mar has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Orchiectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arash Rezazadeh-Kalebasty
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arash Rezazadeh-Kalebasty
Hematology Oncology | Hematology | Oncology

Uc Regents

101 The City Dr S, Uci Dept Of Medicine, 
Orange, CA 
 (10.1 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arash Rezazadeh-Kalebasty is a Hematologist Oncology specialist and a Hematologist in Orange, California. Dr. Rezazadeh-Kalebasty is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Prostate Cancer, Urothelial Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Nephrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Marathe's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 148 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile